Dorzagliatin as a Glucose Sensitizer Achieved Sustained Glycemic Control in Combination with Metformin in Chinese T2DM Patients in a 52-Week Phase 3 Clinical Trial (DAWN Study) -Poster and Presentation-Hua Medicine

CQ9电子·(China)中国区官方网站CQ9电子

Dorzagliatin as a Glucose Sensitizer Achieved Sustained Glycemic Control in Combination with Metformin in Chinese T2DM Patients in a 52-Week Phase 3 Clinical Trial (DAWN Study)

2021 ADA Poster
Nov 02, 2022
3162

Online link unavailable, presentation available upon request. (BD@thanosbox.com)

Focus Us
Copyright © 2025  Hua Medicine (Shanghai) Co., Ltd.    互联网药品信息服务资格证书编号: (沪)-非经营-2022-0079
沪ICP备32850784号-1  beiantubiao.png 沪公网安备 31011502013809号  Privacy Statement  Terms of Use
Search
How we use cookies
Hua Medicine uses cookies to enable and improve the use of the website. By continuing to use the site, you consent to the use of these cookies. To learn more about cookies, please read our privacy statement.
Accept
x
网站首页
CQ9电子